公开(公告)号：KR1020010001605A

公开(公告)日：2001-01-05

申请号：KR1019990020951

申请日：1999-06-07

Applicant: 한국과학기술연구원

Inventor： 유재훈 ,  박호군 ,  천성민 ,  정선주

IPC: C07H21/02

Abstract: PURPOSE: Provided is an RNA sequence which has a binding specificity to cholesterol or derivatives thereof and which has an activity of a cholesterol esterase. Also, provided is a detection method of a lipophilic substance, especially LDL resulting in arteriosclerosis and a hypertension using the RNA sequence. The sequence is useful in an inhibitor blocking a bioreaction caused by endocrine disruptors and is used as an artificial catalyst without any side effect. CONSTITUTION: The RNA sequence is selected from the group consisting of SEQ ID NO : 1 - SEQ ID NO : 11 and has the activity of a cholesterol esterase. The RNA sequence is prepared by a 131 bp DNA sequence comprising 70 nucleotides of random sequence as shown in Fig. 1, wherein T7 RNA polymerase of 5'-primer promotes an in vitro transcription and the site of a restriction enzyme is useful in identifying that the inserts have been incorporated into the sequence. The detection method of the lipophilic substance comprises the steps of : reacting the lipophilic substance with the RNA sequence selected from SEQ ID NO : 1 - SEQ ID NO : 11; and assaying the RNA bonded specifically with the lipophilic substance to detect the lipophilic substance.

Abstract translation: 目的：提供对胆固醇或其衍生物具有结合特异性并具有胆固醇酯酶活性的RNA序列。 此外，提供亲脂性物质的检测方法，特别是导致动脉硬化的LDL和使用RNA序列的高血压。 该序列可用于阻断由内分泌干扰物引起的生物反应的抑制剂，并用作人造催化剂而没有任何副作用。 构成：RNA序列选自SEQ ID NO：1〜SEQ ID NO：11，具有胆固醇酯酶的活性。 RNA序列由包含70个随机序列核苷酸的131bp DNA序列制备，如图1所示。 1，其中5'-引物的T7RNA聚合酶促进体外转录，并且限制酶的位点可用于鉴定插入片段已经并入序列。 亲脂性物质的检测方法包括以下步骤：使亲脂性物质与选自SEQ ID NO：1〜SEQ ID NO：11的RNA序列反应; 并测定与亲脂性物质特异性结合的RNA以检测亲脂性物质。

公开(公告)号：KR100656530B1

公开(公告)日：2006-12-13

申请号：KR1020050002296

申请日：2005-01-10

Applicant: 한국과학기술연구원

Inventor： 양은경 ,  정선주 ,  이수경 ,  박민우

IPC: C12N15/11

Abstract: 본 발명은 RNA 앱타머 및 이의 용도에 관한 것으로서, 보다 구체적으로는 베타-카테닌과 상호작용하는 TCF-1의 N-말단에 특이적으로 결합하는 RNA 앱타머 및 이의 세포 증식성 질환 치료제로서의 용도에 관한 것이다. 본 발명의 RNA 앱타머는 TCF-1과 베타-카테닌 복합체의 형성을 효과적으로 방해하여 세포 증식성 질환 치료제의 개발에 유용하게 이용될 수 있다.
RNA 앱타머, TCF-1, 베타-카테닌

公开(公告)号：KR100520495B1

公开(公告)日：2005-10-11

申请号：KR1020020064986

申请日：2002-10-23

Applicant: 한국과학기술연구원

Inventor： 유재훈 ,  양은경 ,  항투누엔 ,  신병희 ,  정선주

IPC: C07K16/18

Abstract: 본 발명은 베타아밀로이드의 형태를 특이적(specific)으로 인식하는 단일 클론 항체에 관한 것으로서, 상기 항체는 1) 베타아밀로이드 및 상기 베타아밀로이드를 안정한 형태(conformation)로 변형시키는 화합물로 구성된 혼합물을 제조하여 항원으로 사용하고 2) 상기 혼합물을 면역화하는 단계로 제조되는 것이다. 본 발명에 의한 항체는 종래에 베타아밀로이드 단독 또는 단순한 길이의 변화를 조절하여 항원으로 사용하여 제조한 항체에 비하여, 베타아밀로이드-화합물과의 혼합물을 사용하여 가장 안정된 형태의 베타아밀로이드 단위체를 강력하게 인식하는 항체를 제조함으로써, 베타아밀로이드의 집적으로 유발되는 알쯔하이머 병의 치료제로 유용하다.

公开(公告)号：KR100347289B1

公开(公告)日：2002-08-07

申请号：KR1019990020954

申请日：1999-06-07

Applicant: 한국과학기술연구원

Inventor： 유재훈 ,  박호군 ,  정선주 ,  엄태연

IPC: C07H21/02

Abstract: 본발명은암세포의시알릴루이스 X (sLeX)에높은특이성과친화성으로접합하는 RNA서열및 이를이용한 sLeX의탐지방법을제공한다. 시알릴루이스 X (sLeX)는염증과암의전이에관련된세포표면표적자이고, 본발명의선택된 RNA는그 접합강도나분자의특이성면에서우월한결과를가지므로, 이는암세포를특이적으로인식할수 있어암세포의탐지화및 암치료제의개발에획기적인결과를줄 수있는분자가될 수있는잠재력을가지고있다.

公开(公告)号：KR1020010076898A

公开(公告)日：2001-08-17

申请号：KR1020000004317

申请日：2000-01-28

Applicant: 한국과학기술연구원

Inventor： 유재훈 ,  천성민 ,  정선주

IPC: C12N15/00

Abstract: PURPOSE: RNA molecule conjugating with N-acethylneuramine-lactose is provided, which can be effectively used for the treatment of specific cancers or diseases followed by specific inflammation. CONSTITUTION: RNA molecule conjugating with N-acethylneuramine-lactose and having the base sequence of SEQ ID NO: 1 is isolated by the steps of: binding N-acethylneuramine lactose on the solid phase supporter by the covalent bond; binding RNA molecule with the N-acethylneuramine lactose fixed on the solid phase supporter; eluting the bound RNA library by using affinity chromatography; and repeating the steps to isolate RNA molecule strongly conjugating with N-acethylneuramine-lactose.

Abstract translation: 目的：提供与N-乙酰神经胺 - 乳糖共轭的RNA分子，可以有效地用于治疗特定的癌症或疾病，然后特异性炎症。 构成：通过以下步骤分离与N-乙酰甲基甘氨酸 - 乳糖共轭并具有SEQ ID NO：1的碱基序列的RNA分子，其通过共价键结合固相载体上的N-乙酰基三聚氰胺乳糖; 结合RNA分子与固定在固相载体上的N-乙酰基三聚氰胺乳糖; 通过亲和层析洗脱结合的RNA文库; 并重复步骤以分离与N-乙酰神经胺 - 乳糖强烈缀合的RNA分子。

公开(公告)号：KR1020010001606A

公开(公告)日：2001-01-05

申请号：KR1019990020953

申请日：1999-06-07

Applicant: 한국과학기술연구원

Inventor： 유재훈 ,  박호군 ,  천성민 ,  정선주

IPC: C07H21/02

Abstract: PURPOSE: Provided are an RNA sequence which has a binding specificity to kanamycin A and a selection method of the RNA sequence having a high specificity to an antibiotic such as kanamycin A. Because the RNA sequence is readily used in reverse drug discovery, it can cut costs and is useful in searching a novel target molecule to the kanamycin A. CONSTITUTION: The RNA is selected from the group consisting of SEQ ID NO : 1 - SEQ ID NO : 8 and has a binding specificity to kanamycin A. The RNA sequence is prepared by a 131 bp DNA sequence comprising 70 nucleotides of random sequence as shown in Fig. 1, wherein T7 RNA polymerase of 5'-primer promotes an in vitro transcription and the site of a restriction enzyme is useful in identifying that the inserts have been incorporated into the sequence. The selection method of the RNA sequence having a high specificity to the antibiotic comprises reacting the antibiotic fixed to solid phase with 100-200 bp of the RNA sequence ligated with 70 random nucleotides at 5' or 3' end thereof using a systematic evolution of ligand by exponential enrichment (SELEX) method.

Abstract translation: 目的：提供对卡那霉素A具有结合特异性的RNA序列和对抗生素如卡那霉素A具有高特异性的RNA序列的选择方法。因为RNA序列容易用于反向药物发现，因此可以切割 成本并且可用于在卡那霉素A中搜索新的靶分子。构成：RNA选自SEQ ID NO：1 - SEQ ID NO：8，并且对卡那霉素A具有结合特异性.RNA序列是 由包含70个核苷酸的随机序列的131bp DNA序列制备，如图1所示。 1，其中5'-引物的T7RNA聚合酶促进体外转录，并且限制酶的位点可用于鉴定插入片段已被并入序列。 对抗生素具有高特异性的RNA序列的选择方法包括将固定在固相上的抗生素与其5'或3'末端与70个随机核苷酸连接的DNA序列的100-200bp反应，使用配体的系统进化 通过指数富集（SELEX）方法。

公开(公告)号：KR1020060081860A

公开(公告)日：2006-07-13

申请号：KR1020050002296

申请日：2005-01-10

Applicant: 한국과학기술연구원

Inventor： 양은경 ,  정선주 ,  이수경 ,  박민우

IPC: C12N15/11

Abstract: 본 발명은 RNA 앱타머 및 이의 용도에 관한 것으로서, 보다 구체적으로는 베타-카테닌과 상호작용하는 TCF-1의 N-말단에 특이적으로 결합하는 RNA 앱타머 및 이의 세포 증식성 질환 치료제로서의 용도에 관한 것이다. 본 발명의 RNA 앱타머는 TCF-1과 베타-카테닌 복합체의 형성을 효과적으로 방해하여 세포 증식성 질환 치료제의 개발에 유용하게 이용될 수 있다.
RNA 앱타머, TCF-1, 베타-카테닌

公开(公告)号：KR1020040036167A

公开(公告)日：2004-04-30

申请号：KR1020020064986

申请日：2002-10-23

Applicant: 한국과학기술연구원

Inventor： 유재훈 ,  양은경 ,  항투누엔 ,  신병희 ,  정선주

IPC: C07K16/18

CPC classification number: C07K16/18 ,  C07K2317/30

Abstract: PURPOSE: A beta-amyloid specific monoclonal antibody and a method for preparing the same are provided, thereby producing the function-improved antibody which strongly recognizes stable conformation of beta-amyloid by using a beta-amyloid-compound mixture as an antigen, so that the antibody can be useful for treatment of Alzheimer's disease caused by accumulation of beta-amyloid. CONSTITUTION: A monoclonal antibody specifically recognizes beta-amyloid, wherein the monoclonal antibody is prepared by using a mixture of beta-amyloid and a material which modifies the beta-amyloid into the stable conformation as an antigen. A method for preparing the beta-amyloid specific monoclonal antibody comprises the steps of: (1) preparing the mixture of beta-amyloid and the material which modifies the beta-amyloid into the stable conformation; and (2) immunizing the mixture as an antigen, wherein beta-amyloid comprises 1 to 42 amino acids or a portion thereof; and the material which modifies the beta-amyloid into the stable conformation is a compound represented by the formula(1), bio-molecule, or modified bio-molecule.

Abstract translation: 目的：提供β-淀粉样蛋白特异性单克隆抗体及其制备方法，从而产生通过使用β-淀粉样蛋白化合物混合物作为抗原强烈识别β-淀粉样蛋白的稳定构象的功能改善的抗体，使得 该抗体可用于治疗由β-淀粉样蛋白积累引起的阿尔茨海默病。 构成：单克隆抗体特异性识别β-淀粉样蛋白，其中通过使用β-淀粉样蛋白和将β-淀粉样蛋白修饰成稳定构象作为抗原的材料的混合物制备单克隆抗体。 制备β-淀粉样蛋白特异性单克隆抗体的方法包括以下步骤：（1）制备β-淀粉样蛋白和将β-淀粉样蛋白修饰为稳定构象的材料的混合物; 和（2）将该混合物免疫作为抗原，其中β-淀粉样蛋白包含1至42个氨基酸或其部分; 并且将β-淀粉样蛋白修饰为稳定构象的材料是由式（1），生物分子或修饰的生物分子表示的化合物。

公开(公告)号：KR1020010076994A

公开(公告)日：2001-08-17

申请号：KR1020000004484

申请日：2000-01-29

Applicant: 한국과학기술연구원

Inventor： 유재훈 ,  박호군 ,  윤현주 ,  정선주 ,  최소영 ,  권미윤

IPC: C07H21/00

Abstract: PURPOSE: Provided is DNA sequence that codes variable region of an antibody having enzymatic activity degrading glycosidic bond. And its expression method is also provided. CONSTITUTION: A DNA sequence coding variable region of an antibody having enzymatic activity degrading glycosidic bond is as follows: DNA sequence represented by sequence ID. No. 1 coding VH chain of antibody for glycosidase, 4f4r; DNA sequence represented by sequence ID. No. 3 coding VH chain of antibody for glycosidase, 6h4h; DNA sequence represented by sequence ID. No. 5 coding VH chain of antibody for glycosidase, Ab2l; DNA sequence represented by sequence ID. No. 7 coding antibody for glycosidase, 4f4r; DNA sequence represented by sequence ID. No. 9 coding VL chain of antibody for glycosidase, 6h4h; or DNA sequence represented by sequence ID. No. 11 coding VL chain of antibody for glycosidase, Ab2l. Wherein, all sequences are described as in the description. The antibody is prepared by expressing a fusion protein of VH and VL in an eukaryote cell or bacteria.

Abstract translation: 目的：提供编码具有酶活性降解糖苷键的抗体的可变区的DNA序列。 并提供其表达方法。 构成：具有酶活性降解糖苷键的抗体的编码可变区的DNA序列如下：由序列ID表示的DNA序列。 1号编码糖苷酶抗体的VH链，4f4r; 由序列ID表示的DNA序列。 3号编码糖苷酶抗体VH链，6h4h; 由序列ID表示的DNA序列。 编码糖基化抗体的第5号VH链，Ab2l; 由序列ID表示的DNA序列。 糖苷酶7号编码抗体，4f4r; 由序列ID表示的DNA序列。 9号编码糖苷酶抗体VL链，6h4h; 或由序列ID表示的DNA序列。 11号编码糖苷酶抗体的VL链，Ab2l。 其中所有序列如描述中所述。 通过在真核细胞或细菌中表达VH和VL的融合蛋白来制备抗体。